单分子高敏肌钙蛋白I与稳定性胸痛患者短期风险
本研究基于PROMISE试验中4021例稳定性胸痛疑似冠心病门诊患者,分析单分子计数高敏肌钙蛋白I(hsTnI,正常范围<6 ng/l)与1年内死亡、急性心梗或 unstable angina 住院的关系。结果发现98.6%患者可测得hsTnI,中位值1.6 ng/l,较高hsTnI浓度独立预测主要终点(HR 1.54,p<0.001)且与近期事件关联更强。
要点
- 稳定性胸痛疑似冠心病患者中,hsTnI在正常范围内即可预测1年内死亡、心梗或住院风险。
- hsTnI每升高对数四分位间距,主要终点风险增加54%,心血管死亡或心梗风险增加52%。
- hsTnI与近期事件的关联强于长期随访,提示可用于短期风险分层。
核心结论
- 在稳定性胸痛疑似冠心病门诊患者中,正常范围内较高的hsTnI浓度与短期死亡、急性心梗或 unstable angina 住院风险升高相关。
研究设计与样本
- 基于PROMISE前瞻性多中心成像研究,纳入4021例有可用血样的稳定性胸痛疑似冠心病门诊患者,分析hsTnI与1年结局的关系。
主要发现
- 98.6%的参与者可测得hsTnI,中位值为1.6 ng/l。
- hsTnI较高四分位组患者具有更高危的临床特征。
- hsTnI浓度越高,死亡、急性心梗或 unstable angina 住院的事件概率越大。
- 多变量模型中,hsTnI独立预测主要终点(HR 1.54每对数四分位间距增加,p<0.001)和心血管死亡或急性心梗(HR 1.52,p<0.001)。
- 与较长随访相比,hsTnI与近期事件的关联更强。
临床怎么用
- 对于稳定性胸痛疑似冠心病门诊患者,可考虑检测单分子hsTnI以辅助短期风险分层。
- 即使hsTnI处于正常范围(<6 ng/l),较高浓度仍提示近期事件风险增加,需加强评估与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evaluation of stable symptomatic outpatients with suspected coronary artery disease (CAD) may be challenging because they have a wide range of cardiovascular risk. The role of troponin testing to assist clinical decision making in this setting is unexplored. OBJECTIVES: This study sought to evaluate the prognostic meaning of single-molecule counting high-sensitivity troponin I (hsTnI) (normal range <6 ng/l) among outpatients with stable chest symptoms and suspected CAD. METHODS: Participants with available blood samples in PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) were studied, and hsTnI results were analyzed relative to the primary outcome of death, acute myocardial infarction (MI), or hospitalization for unstable angina by 1 year. The secondary outcome was the composite of cardiovascular death or acute MI. RESULTS: The study sample consisted of 4,021 participants; 98.6% had measurable hsTnI concentrations. The median hsTnI value was 1.6 ng/l. In upper hsTnI quartiles, patients had higher-risk clinical profiles. Higher hsTnI concentrations were associated with greater event probabilities for death, acute MI, or hospitalization for unstable angina. In multivariable models, hsTnI concentrations independently predicted death, acute MI, or hospitalization for unstable angina (hazard ratio: 1.54 per increase in log-hsTnI interquartile range; p < 0.001) and cardiovascular death or acute MI (hazard ratio: 1.52 per increase in log-hsTnI interquartile range; p < 0.001) and were particularly associated with near-term events, compared with longer follow-up. CONCLUSIONS: In symptomatic outpatients with suspected CAD, higher concentrations of hsTnI within the normal range were associated with heightened near-term risk for death, acute MI, or hospitalization. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).
引用
- Januzzi JL, Suchindran S, Hoffmann U, et al. Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain. J Am Coll Cardiol. 2019. PMID: 30678753. doi:10.1016/j.jacc.2018.10.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。